Small Dense LDL (sdLDL)

Metabolic

Lipid Metabolism

Small dense LDL (sdLDL) refers to LDL particles that are smaller and denser than usual, allowing them to slip into the artery wall more easily. These are considered the most dangerous form of LDL, more atherogenic than large, buoyant particles. A longevity practice measures sdLDL to distinguish a favorable Pattern A lipid profile from a higher-risk Pattern B one.

What It Measures

Small, dense LDL particles that penetrate arterial walls more easily; more atherogenic than large buoyant LDL

Optimal vs. Lab Range

Longevity Optimal

Pattern A (large buoyant) preferred over Pattern B (small dense)

Target range for optimal health and longevity based on research.

Standard Lab

Varies by method

Population-based reference range from standard labs.

Why It Matters

Because small dense particles penetrate the arterial wall more readily and resist clearance, sdLDL is the more atherogenic LDL subtype and a Pattern B profile carries higher cardiovascular risk than Pattern A. A predominance of small dense particles is strongly tied to metabolic syndrome, insulin resistance, and high triglycerides, so it often signals metabolic dysfunction as well as lipid risk. This dual meaning makes it especially useful in a longevity context, connecting lipid and metabolic health in one marker. It is interpreted with LDL-P, ApoB, triglycerides, the TG/HDL ratio, and fasting insulin. A shift toward large buoyant particles is generally favorable.

When Low

Generally favorable when low

When High

Metabolic syndrome, insulin resistance, high triglycerides; sdLDL is the "dangerous" LDL

How to Optimize

Because small dense particles are driven largely by insulin resistance and high triglycerides, carbohydrate restriction is particularly effective at shifting the profile toward larger, less harmful particles. Regular exercise and broader metabolic optimization reinforce that shift. Omega-3 fatty acids help by lowering triglycerides, a key driver of the small dense pattern. Retesting shows whether the profile is moving from Pattern B toward Pattern A. Targets and treatment are individualized with your physician; this content is educational and not a substitute for medical advice.

Key Interventions & Linked Compounds

Moderate evidence

Key Interventions

Carb restriction

omega-3

exercise

metabolic optimization

Linked Compounds & Supplements

Omega-3

Berberine

Niacin

Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

Ordering Notes

Specimen

Serum or plasma (venous draw)

Patient prep

No fasting required. Maintain usual diet and medications unless advised.

Recommended cadence

Annual

Reporting unit

Confirm with the performing lab — units vary by region.

Pre-analytic notes

Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

Recommended Follow-Up Actions

1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift Small Dense LDL (sdLDL).
2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.